AdHER2/neu DC Vaccine / National Cancer Institute - LARVOL DELTA

ImmunityBio Announces Study of ANKTIVA in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer (Businesswire) - "Immunotherapy company ImmunityBio, Inc...announced the opening of a clinical trial to study ANKTIVA (nogapendekin alfa inbakicept-pmln) together with the investigational AdHER2DC vaccine (autologous dendritic cells transduced with HER2 expressing adenovirus), in individuals with HER2-expressing endometrial cancer...This Phase 1/2 QUILT 502 trial (NCT06253494) sponsored by the National Cancer Institute, part of the National Institutes of Health, will study whether the AdHER2DC vaccine in combination with ANKTIVA, pembrolizumab (checkpoint inhibitor), and lenvatinib (kinase inhibitor) can be safely administered in combination and provide preliminary clinical efficacy before a larger, more definitive study....The study will enroll 60 subjects and is expected to be completed in 2026."

Trial completion date • Trial status • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=33; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2022 ➔ Dec 2021

Clinical • Trial completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=33; Completed; Sponsor: National Cancer Institute (NCI); Active, not recruiting ➔ Completed; Trial completion date: Dec 2021 ➔ Dec 2019; Trial primary completion date: Dec 2021 ➔ Dec 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=31; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting; N=65 ➔ 31

Clinical • Enrollment change • Enrollment closed • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Nov 2017 ➔ Dec 2018

Clinical • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Dec 2018 ➔ Dec 2021

Clinical • Trial primary completion date • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Non Small Cell Lung Cancer • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jun 2015 ➔ Nov 2016

Clinical • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • HER-2

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Nov 2016 ➔ Nov 2017

Clinical • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • HER-2